Putative correlates of protection against shigellosis assessing immunomarkers across responses to S. sonnei investigational vaccine.
Journal
NPJ vaccines
ISSN: 2059-0105
Titre abrégé: NPJ Vaccines
Pays: England
ID NLM: 101699863
Informations de publication
Date de publication:
08 Mar 2024
08 Mar 2024
Historique:
received:
31
08
2023
accepted:
30
01
2024
medline:
9
3
2024
pubmed:
9
3
2024
entrez:
8
3
2024
Statut:
epublish
Résumé
Shigella spp. are a leading bacterial cause of diarrhea. No widely licensed vaccines are available and there is no generally accepted correlate of protection. We tested a S. sonnei Generalized Modules for Membrane Antigen (GMMA)-based vaccine (1790GAHB) in a phase 2b, placebo-controlled, randomized, controlled human infection model study (NCT03527173) enrolling healthy United States adults aged 18-50 years. We report analyses evaluating immune responses to vaccination, with the aim to identify correlates of risk for shigellosis among assessed immunomarkers. We found that 1790GAHB elicited S. sonnei lipopolysaccharide specific α4β7+ immunoglobulin (Ig) G and IgA secreting B cells which are likely homing to the gut, indicating the ability to induce a mucosal in addition to a systemic response, despite parenteral delivery. We were unable to establish or confirm threshold levels that predict vaccine efficacy facilitating the evaluation of vaccine candidates. However, serum anti-lipopolysaccharide IgG and bactericidal activity were identified as potential correlates of risk for shigellosis.
Identifiants
pubmed: 38459072
doi: 10.1038/s41541-024-00822-2
pii: 10.1038/s41541-024-00822-2
doi:
Types de publication
Journal Article
Langues
eng
Pagination
56Informations de copyright
© 2024. GlaxoSmithKline Biologicals S.A.
Références
Khalil, I. A. et al. Morbidity and mortality due to shigella and enterotoxigenic Escherichia coli diarrhoea: the Global Burden of Disease Study 1990-2016. Lancet Infect. Dis. 18, 1229–1240 (2018).
pubmed: 30266330
pmcid: 6202441
doi: 10.1016/S1473-3099(18)30475-4
Libby, T. E. et al. Consequences of Shigella infection in young children: a systematic review. Int. J. Infect. Dis. 129, 78–95 (2023).
pubmed: 36736579
pmcid: 10017352
doi: 10.1016/j.ijid.2023.01.034
Nasrin, D. et al. Pathogens associated with linear growth faltering in children with diarrhea and impact of antibiotic treatment: The Global Enteric Multicenter Study. J. Infect. Dis. 224, S848–S855 (2021).
pubmed: 34528677
pmcid: 8958895
doi: 10.1093/infdis/jiab434
Shad, A. A. & Shad, W. A. Shigella sonnei: virulence and antibiotic resistance. Arch. Microbiol. 203, 45–58 (2021).
pubmed: 32929595
doi: 10.1007/s00203-020-02034-3
Anderson, M., Sansonetti, P. J. & Marteyn, B. S. Shigella diversity and changing landscape: insights for the twenty-first century. Front. Cell. Infect. Microbiol. 6, 45 (2016).
pubmed: 27148494
pmcid: 4835486
doi: 10.3389/fcimb.2016.00045
Ranjbar, R. & Farahani, A. Shigella: antibiotic-resistance mechanisms and new horizons for treatment. Infect. Drug Resist. 12, 3137–3167 (2019).
pubmed: 31632102
pmcid: 6789722
doi: 10.2147/IDR.S219755
Shakoor, S., Platts-Mills, J. A. & Hasan, R. Antibiotic-resistant enteric infections. Infect. Dis. Clin. North Am. 33, 1105–1123 (2019).
pubmed: 31668193
doi: 10.1016/j.idc.2019.05.007
MacLennan, C. A., Grow, S., Ma, L. F. & Steele, A. D. The Shigella vaccines pipeline. Vaccines 10, 1376 (2022).
pubmed: 36146457
pmcid: 9504713
doi: 10.3390/vaccines10091376
Raso, M. M., Arato, V., Gasperini, G. & Micoli, F. Toward a Shigella vaccine: opportunities and challenges to fight an antimicrobial-resistant pathogen. Int. J. Mol. Sci. 24, 4649 (2023).
pubmed: 36902092
pmcid: 10003550
doi: 10.3390/ijms24054649
Cohen, D. et al. Serum IgG antibodies to Shigella lipopolysaccharide antigens - a correlate of protection against shigellosis. Hum. Vaccin. Immunother. 15, 1401–1408 (2019).
pubmed: 31070988
pmcid: 6663123
doi: 10.1080/21645515.2019.1606971
Black, R. E. et al. Prevention of shigellosis by a Salmonella typhi-Shigella sonnei bivalent vaccine. J. Infect. Dis. 155, 1260–1265 (1987).
pubmed: 2437220
doi: 10.1093/infdis/155.6.1260
Cohen, D. et al. Serum antibodies to lipopolysaccharide and natural immunity to shigellosis in an Israeli military population. J. Infect. Dis. 157, 1068–1071 (1988).
pubmed: 3283258
doi: 10.1093/infdis/157.5.1068
Cohen, D. et al. Threshold protective levels of serum IgG to Shigella lipopolysaccharide: re-analysis of Shigella vaccine trials data. Clin. Microbiol. Infect. 29, 366–371 (2023).
pubmed: 36243351
pmcid: 9993342
doi: 10.1016/j.cmi.2022.10.011
Clarkson, K. A. et al. Immune response characterization after controlled infection with lyophilized Shigella sonnei 53G. mSphere 5, e00988–00919 (2020).
pubmed: 32968012
pmcid: 7568644
doi: 10.1128/mSphere.00988-19
Clarkson, K. A. et al. Shigella-specific immune profiles induced after parenteral immunization or oral challenge with either Shigella flexneri 2a or Shigella sonnei. mSphere 6, e0012221 (2021).
pubmed: 34259559
doi: 10.1128/mSphere.00122-21
Feller, A. J. et al. Comparative evaluation of the antibody in lymphocyte supernatant (ALS) and enzyme-linked immunospot (ELISPOT) assays for measuring mucosal immune responses to Shigella antigens. Vaccine 29, 8487–8489 (2011).
pubmed: 21939714
pmcid: 3216048
doi: 10.1016/j.vaccine.2011.09.030
Kotloff, K. L. et al. A modified Shigella volunteer challenge model in which the inoculum is administered with bicarbonate buffer: clinical experience and implications for Shigella infectivity. Vaccine 13, 1488–1494 (1995).
pubmed: 8578831
doi: 10.1016/0264-410X(95)00102-7
Micoli, F. et al. Antibodies elicited by the Shigella sonnei GMMA vaccine in adults trigger complement-mediated serum bactericidal activity: results from a phase 1 dose escalation trial followed by a booster extension. Front. Immunol. 12, 671325 (2021).
pubmed: 34017343
pmcid: 8129577
doi: 10.3389/fimmu.2021.671325
Ndungo, E. & Pasetti, M. F. Functional antibodies as immunological endpoints to evaluate protective immunity against Shigella. Hum. Vaccin. Immunother. 16, 197–205 (2020).
pubmed: 31287754
doi: 10.1080/21645515.2019.1640427
Sarker, P. et al. Functional antibodies and innate immune responses to WRSS1, a live oral Shigella sonnei vaccine candidate, in Bangladeshi adults and children. J. Infect. Dis. 224, S829–S839 (2021).
pubmed: 34374425
pmcid: 8687094
doi: 10.1093/infdis/jiab395
Sinha, A. et al. Circulating gut-homing (α4β7+) plasmablast responses against Shigella surface protein antigens among hospitalized patients with diarrhea. Clin. Vaccine Immunol. 23, 610–617 (2016).
pubmed: 27193041
pmcid: 4933774
doi: 10.1128/CVI.00205-16
Mancini, F. et al. GMMA-based vaccines: the known and the unknown. Front. Immunol. 12, 715393 (2021).
pubmed: 34413858
pmcid: 8368434
doi: 10.3389/fimmu.2021.715393
Piccioli, D., Bartolini, E. & Micoli, F. GMMA as a ‘plug and play’ technology to tackle infectious disease to improve global health: context and perspectives for the future. Expert Rev. Vaccines 21, 163–172 (2022).
pubmed: 34913415
doi: 10.1080/14760584.2022.2009803
Micoli, F. & MacLennan, C. A. Outer membrane vesicle vaccines. Semin. Immunol. 50, 101433 (2020).
pubmed: 33309166
doi: 10.1016/j.smim.2020.101433
Mancini, F., Rossi, O., Necchi, F. & Micoli, F. OMV vaccines and the role of TLR agonists in immune response. Int. J. Mol. Sci. 21, 4416 (2020).
pubmed: 32575921
pmcid: 7352230
doi: 10.3390/ijms21124416
Rossi, O. et al. Modulation of endotoxicity of Shigella generalized modules for membrane antigens (GMMA) by genetic lipid A modifications: relative activation of TLR4 and TLR2 pathways in different mutants. J. Biol. Chem. 289, 24922–24935 (2014).
pubmed: 25023285
pmcid: 4155660
doi: 10.1074/jbc.M114.566570
Micoli, F., Nakakana, U. N. & Berlanda Scorza, F. Towards a four-component GMMA-based vaccine against Shigella. Vaccines 10, 328 (2022).
pubmed: 35214786
pmcid: 8880054
doi: 10.3390/vaccines10020328
De Ryck, I. et al. GMMA technology for the development of safe vaccines: meta-analysis of individual patient data to assess the safety profile of Shigella sonnei 1790GAHB vaccine in healthy adults, with special focus on neutropenia. Infect. Dis. Ther. 11, 757–770 (2022).
pubmed: 35118580
pmcid: 8960504
doi: 10.1007/s40121-022-00596-x
Kapulu, M. C. et al. Complement-mediated serum bactericidal activity of antibodies elicited by the Shigella sonnei GMMA vaccine in adults from a shigellosis-endemic country: Exploratory analysis of a Phase 2a randomized study. Front. Immunol. 13, 971866 (2022).
pubmed: 36203568
pmcid: 9531247
doi: 10.3389/fimmu.2022.971866
Obiero, C. W. et al. A phase 2a randomized study to evaluate the safety and immunogenicity of the 1790GAHB generalized modules for membrane antigen vaccine against Shigella sonnei administered intramuscularly to adults from a shigellosis-endemic country. Front. Immunol. 8, 1884 (2017).
pubmed: 29375556
pmcid: 5763125
doi: 10.3389/fimmu.2017.01884
Launay, O. et al. Safety profile and immunologic responses of a novel vaccine against Shigella sonnei administered intramuscularly, intradermally and intranasally: results from two parallel randomized phase 1 clinical studies in healthy adult volunteers in Europe. EBioMedicine 22, 164–172 (2017).
pubmed: 28735965
pmcid: 5552227
doi: 10.1016/j.ebiom.2017.07.013
Launay, O. et al. Booster vaccination with Gvgh Shigella sonnei 1790GAHB GMMA vaccine compared to single vaccination in unvaccinated healthy European Adults: results from a phase 1 clinical trial. Front. Immunol. 10, 335 (2019).
pubmed: 30906291
pmcid: 6418009
doi: 10.3389/fimmu.2019.00335
Frenck, R. W. Jr et al. Efficacy, safety, and immunogenicity of the Shigella sonnei 1790GAHB GMMA candidate vaccine: results from a phase 2b randomized, placebo-controlled challenge study in adults. EClinicalMedicine 39, 101076 (2021).
pubmed: 34430837
pmcid: 8367798
doi: 10.1016/j.eclinm.2021.101076
Prentice, R. L. Surrogate endpoints in clinical trials: definition and operational criteria. Stat. Med. 8, 431–440 (1989).
pubmed: 2727467
doi: 10.1002/sim.4780080407
Qin, L. et al. A framework for assessing immunological correlates of protection in vaccine trials. J. Infect. Dis. 196, 1304–1312 (2007).
pubmed: 17922394
doi: 10.1086/522428
Frenck, R. W. et al. Establishment of a controlled human infection model with a lyophilized strain of Shigella sonnei 53G. mSphere 5, e00416–e00420 (2020).
pubmed: 32968005
pmcid: 7568646
doi: 10.1128/mSphere.00416-20
Frenck, R. W. et al. A phase I trial to evaluate the safety and immunogenicity of WRSs2 and WRSs3; two live oral candidate vaccines against Shigella sonnei. Vaccine 36, 4880–4889 (2018).
pubmed: 30037478
pmcid: 10559265
doi: 10.1016/j.vaccine.2018.06.063
Raqib, R. et al. A phase I trial of WRSS1, a Shigella sonnei live oral vaccine in Bangladeshi adults and children. Hum. Vaccin. Immunother. 15, 1326–1337 (2019).
pubmed: 30794051
pmcid: 6663145
doi: 10.1080/21645515.2019.1575165
Clarkson, K. A. et al. Immune response characterization in a human challenge study with a Shigella flexneri 2a bioconjugate vaccine. EBioMedicine 66, 103308 (2021).
pubmed: 33813141
pmcid: 8047506
doi: 10.1016/j.ebiom.2021.103308
Plotkin, S. A. Recent updates on correlates of vaccine-induced protection. Front. Immunol. 13, 1081107 (2023).
pubmed: 36776392
pmcid: 9912984
doi: 10.3389/fimmu.2022.1081107
Cohen, D. et al. Safety and immunogenicity of a synthetic carbohydrate conjugate vaccine against Shigella flexneri 2a in healthy adult volunteers: a phase 1, dose-escalating, single-blind, randomised, placebo-controlled study. Lancet Infect. Dis. 21, 546–558 (2021).
pubmed: 33186516
doi: 10.1016/S1473-3099(20)30488-6
Cohen, D. et al. Prospective study of the association between serum antibodies to lipopolysaccharide O antigen and the attack rate of shigellosis. J. Clin. Microbiol. 29, 386–389 (1991).
pubmed: 1706731
pmcid: 269772
doi: 10.1128/jcm.29.2.386-389.1991
Shimanovich, A. A. et al. Functional and antigen-specific serum antibody levels as correlates of protection against shigellosis in a controlled human challenge study. Clin. Vaccine Immunol. 24, e00412–e00416 (2017).
pubmed: 27927680
pmcid: 5299116
doi: 10.1128/CVI.00412-16
Burton, D. R. & Woof, J. M. Human antibody effector function. Adv. Immunol. 51, 1–84 (1992).
pubmed: 1502974
doi: 10.1016/S0065-2776(08)60486-1
Kaminski, R. W. et al. Consensus report on Shigella controlled human infection model: immunological assays. Clin. Infect. Dis. 69, S596–S601 (2019).
pubmed: 31816067
pmcid: 6901123
doi: 10.1093/cid/ciz909
Mancini, F. et al. Exploring the role of GMMA components in the immunogenicity of a 4-valent vaccine against Shigella. Int. J. Mol. Sci. 24, 2742 (2023).
pubmed: 36769063
pmcid: 9916818
doi: 10.3390/ijms24032742
Mancini, F. et al. Dissecting the contribution of O-antigen and proteins to the immunogenicity of Shigella sonnei generalized modules for membrane antigens (GMMA). Sci. Rep. 11, 906 (2021).
pubmed: 33441861
pmcid: 7806729
doi: 10.1038/s41598-020-80421-y
Giersing, B. K. et al. How can controlled human infection models accelerate clinical development and policy pathways for vaccines against Shigella? Vaccine 37, 4778–4783 (2019).
pubmed: 31358238
doi: 10.1016/j.vaccine.2019.03.036
Rossi, O. et al. Intra-laboratory evaluation of luminescence based high-throughput serum bactericidal assay (L-SBA) to determine bactericidal activity of human sera against Shigella. High Throughput 9, 14 (2020).
pubmed: 32521658
pmcid: 7361673
doi: 10.3390/ht9020014
Firth, D. Bias reduction of maximum likelihood estimates. Biometrika 80, 27–38 (1993).
doi: 10.1093/biomet/80.1.27
Siber, G. R. et al. Estimating the protective concentration of anti-pneumococcal capsular polysaccharide antibodies. Vaccine 25, 3816–3826 (2007).
pubmed: 17368878
doi: 10.1016/j.vaccine.2007.01.119
Miettinen, O. & Nurminen, M. Comparative analysis of two rates. Stat. Med. 4, 213–226 (1985).
pubmed: 4023479
doi: 10.1002/sim.4780040211